CEP290 Antibody

What criteria should I consider when selecting a CEP290 antibody for my research?

When selecting a CEP290 antibody, consider: (1) Antibody type (monoclonal vs. polyclonal) based on your application needs—monoclonal antibodies like CEP290 Antibody (B-7) offer high specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes ; (2) Host species (rabbit, mouse) to avoid cross-reactivity with your experimental system; (3) Validated applications (WB, IP, IF, ELISA) relevant to your experiments—for example, sc-390462 is validated for WB, IP, IF, and ELISA ; (4) Target epitope location—antibodies targeting different regions may yield different results (e.g., N-terminal vs. C-terminal domains); and (5) Quality of validation data provided by manufacturers, including knockout validation studies .

How can I validate a CEP290 antibody before using it in my critical experiments?

Proper antibody validation should include: (1) Positive controls using cells/tissues known to express CEP290 (e.g., HEK-293, HeLa, K-562 cells) ; (2) Negative controls using CEP290 knockout cell lines, when available ; (3) Peptide competition assays to confirm specificity; (4) Cross-validation using multiple antibodies targeting different CEP290 epitopes; and (5) Validation across multiple experimental techniques (WB, IF, IP). For Western blot validation, verify that the observed molecular weight matches the expected size (~290 kDa, though some isoforms may appear at ~180 kDa) . Additionally, siRNA-mediated knockdown of CEP290 can provide further validation by showing decreased antibody signal .

What dilutions should I use for CEP290 antibodies in different applications?

Optimal dilutions vary by application and specific antibody:

Always perform titration experiments to determine optimal concentration for your specific experimental system, as sensitivity may vary with cell type and expression level .

What are the best fixation and permeabilization methods for CEP290 immunofluorescence staining?

For optimal CEP290 immunofluorescence: (1) Fix cells with 4% paraformaldehyde for 15-20 minutes at room temperature, as this preserves cellular architecture while maintaining antigen accessibility; (2) Permeabilize with 0.2-0.5% Triton X-100 for 5-10 minutes—this is particularly important for CEP290 detection as it's localized to centrosomes and cilia which require adequate permeabilization for antibody access ; (3) Block with 5% BSA for at least 30 minutes to reduce non-specific binding ; (4) Use primary antibody dilutions of approximately 1:100-1:200 and incubate overnight at 4°C; (5) Include acetylated α-tubulin co-staining to mark ciliary structures for co-localization studies . Note that methanol fixation may be preferable for certain centrosomal epitopes, so comparing both methods may be necessary for optimal results.

How can I optimize Western blotting protocols for detecting CEP290?

For successful CEP290 Western blotting: (1) Use fresh lysates prepared with RIPA buffer containing protease inhibitors; (2) Include 1 mM PMSF and phosphatase inhibitors to prevent protein degradation; (3) Employ gradient gels (4-15%) to effectively resolve this large protein (~290 kDa); (4) Extend transfer time (3-4 hours or overnight at low voltage) to ensure complete transfer of this high molecular weight protein; (5) Block with 5% non-fat dry milk in TBS-T for 1 hour at room temperature; (6) Incubate with primary antibody (1:1000 dilution) overnight at 4°C ; (7) Use secondary antibodies at 1:20,000 dilution for optimal signal-to-noise ratio . For troubleshooting weak signals, consider using more concentrated lysates or signal enhancers such as HRP-conjugated secondary antibodies for direct detection .

What controls should I include when performing co-immunoprecipitation with CEP290 antibodies?

Essential controls for CEP290 co-immunoprecipitation include: (1) IgG isotype control from the same species as the CEP290 antibody to identify non-specific binding; (2) Input sample (5-10% of pre-IP lysate) to verify target protein presence; (3) Unbound fraction to assess IP efficiency; (4) Reciprocal IP using antibodies against suspected interaction partners (e.g., RPGR, p150^Glued, KIF3A) ; (5) Negative control using cells lacking or depleted of CEP290; and (6) IP in both native and denaturing conditions to distinguish direct versus indirect interactions. When investigating novel interactions, confirm findings using multiple approaches: for example, research has shown CEP290 interaction with olfactory G proteins (G^olf, Gγ13) and Nrf2 through complementary techniques beyond co-IP.

How can I use CEP290 antibodies to study ciliopathies in cellular and animal models?

To effectively study ciliopathies using CEP290 antibodies: (1) Design experiments comparing ciliary localization patterns in wild-type versus disease models using immunofluorescence microscopy with co-staining for ciliary markers (acetylated α-tubulin, ARL13B) ; (2) Quantify changes in CEP290 protein levels and localization in patient-derived cells versus controls using Western blotting and subcellular fractionation; (3) Utilize the rd16/rd16 mouse model, which carries an in-frame deletion in Cep290, for in vivo studies ; (4) Employ electrophysiological techniques alongside immunostaining to correlate protein mislocalization with functional defects, as demonstrated in studies of olfactory dysfunction in LCA patients with CEP290 mutations ; (5) Develop rescue experiments using gene therapy approaches targeting specific CEP290 domains—studies have shown that C-terminal domains can complement mutant CEP290 function in mouse models .

What approaches can resolve contradictory data regarding CEP290 localization and function?

When faced with contradictory CEP290 data: (1) Systematically compare antibodies targeting different CEP290 epitopes, as accessibility may vary depending on protein conformation or interaction partners; (2) Evaluate fixation methods, as different protocols may reveal distinct subcellular localizations—paraformaldehyde preserves membranes while methanol better exposes some centrosomal antigens; (3) Consider cell-type specific differences, as CEP290 fulfills diverse functions across tissues (photoreceptors versus kidney cells) ; (4) Use super-resolution microscopy techniques (STED, STORM) for precise localization at the centrosome/transition zone; (5) Complement antibody studies with tagged CEP290 constructs and live-cell imaging; and (6) Implement domain-specific functional studies—CEP290 contains multiple functional domains with distinct roles in ciliogenesis, protein transport, and signaling . For example, contradictions in ciliary versus centrosomal localization may reflect CEP290's dynamic distribution during the cell cycle or ciliogenesis processes.

How can CEP290 antibodies be employed in gene therapy research for CEP290-related diseases?

For gene therapy research: (1) Use CEP290 antibodies to validate expression of therapeutic constructs in preclinical models—particularly important given CEP290's large size (7.4 kb coding sequence) which exceeds AAV vector capacity ; (2) Develop domain-specific antibodies to evaluate partial protein complementation approaches, as demonstrated with the C-terminal domain rescue in rd16/rd16 mice ; (3) Implement CRISPR-Cas9 genomic editing validation using Western blotting with CEP290 antibodies to confirm protein restoration or reduction ; (4) Design dual immunofluorescence experiments to assess proper localization of CEP290 and interacting partners following gene therapy; (5) Apply quantitative immunohistochemistry to measure restoration of CEP290 expression across treated tissues; and (6) Correlate protein expression with functional outcomes using tissue-specific assays (e.g., electroretinography for retinal function, olfactory testing for smell function) . Such comprehensive analysis is crucial as even partial restoration of CEP290 function may provide significant therapeutic benefit in hypomorphic conditions.

How can I address non-specific binding issues when using CEP290 antibodies?

To reduce non-specific binding: (1) Increase blocking stringency using 5% BSA combined with 5% normal serum from the secondary antibody host species; (2) Extend blocking time to 1-2 hours at room temperature; (3) Add 0.1-0.3% Triton X-100 to wash buffers to reduce hydrophobic interactions; (4) Increase salt concentration in wash buffers (up to 500 mM NaCl) to disrupt weak ionic interactions; (5) Pre-adsorb antibodies against fixed cells lacking CEP290 or tissues from knockout models when available; (6) Consider using monoclonal antibodies like B-7 (sc-390462) which generally offer higher specificity than polyclonal antibodies ; and (7) Validate results with multiple antibodies targeting different epitopes. For Western blots specifically, membrane washing with 0.05-0.1% SDS can help reduce background while maintaining specific signal.

What strategies can overcome detection challenges for CEP290 in tissues with low expression?

For detecting low CEP290 expression: (1) Implement signal amplification systems such as tyramide signal amplification (TSA) for immunofluorescence or chemiluminescent substrates with extended reaction times for Western blotting; (2) Use antibody-conjugated formats such as HRP-conjugated (sc-390462 HRP) or fluorophore-conjugated antibodies (sc-390462 AF488) for direct detection with increased sensitivity ; (3) Concentrate protein samples using immunoprecipitation before Western blotting; (4) For tissue sections, optimize antigen retrieval methods—citrate buffer (pH 6.0) heated to 95-100°C for 20 minutes often improves accessibility of centrosomal/ciliary antigens; (5) Extend primary antibody incubation to 48-72 hours at 4°C for tissue sections; and (6) Consider using ultrasensitive detection methods such as proximity ligation assay (PLA) to visualize CEP290 interactions even with low protein abundance.

How can I quantitatively analyze CEP290 expression patterns across different experimental conditions?

For quantitative CEP290 analysis: (1) Establish standardized image acquisition parameters ensuring signals remain within linear detection range; (2) Use internal loading controls for Western blot normalization—note that typical housekeeping proteins may not be appropriate for ciliopathy studies as they can be affected by cell cycle perturbations; (3) Implement automated image analysis workflows using ImageJ/Fiji with consistent thresholding methods across all experimental conditions; (4) For immunofluorescence quantification, measure integrated density values rather than simple intensity measurements ; (5) Employ semi-quantitative IHC analysis using "image-pro_plus" software to calculate average density (IOD/area) in both control and experimental regions ; (6) For complex localization patterns, use distance mapping from reference structures (e.g., distance from basal body); and (7) Consider flow cytometry-based approaches for high-throughput quantification of CEP290 in cell populations. Statistical analysis should include appropriate tests for distribution and variance when comparing across experimental conditions.

How can CEP290 antibodies be used to investigate non-ciliary functions of CEP290 in disease contexts?

Beyond ciliopathies, use CEP290 antibodies to: (1) Investigate CEP290's role in hepatocellular carcinoma progression through Western blotting and IHC analysis, as CEP290 expression correlates with AFP levels, TNM stage, and vascular invasion ; (2) Examine CEP290's interaction with the Nrf2 signaling pathway in cancer cells using co-immunoprecipitation and protein expression analysis of pathway members ; (3) Study CEP290's role in ferroptosis by measuring Fe^2+ and malondialdehyde levels in CEP290-knockdown cells compared to controls ; (4) Investigate CEP290's function in activating ATF4-mediated transcription using chromatin immunoprecipitation (ChIP) assays with CEP290 antibodies ; (5) Explore potential connections between CEP290 and autophagy pathways through co-localization studies with autophagosome markers; and (6) Examine CEP290's potential functions in immune cells, as several ciliary proteins have been implicated in immunological synapse formation. These approaches extend our understanding of CEP290 beyond its canonical ciliary functions.

What experimental approaches can determine tissue-specific functions of CEP290 using antibodies?

To investigate tissue-specific functions: (1) Perform comparative immunohistochemistry across multiple tissues in wild-type and disease models using standardized antibody dilutions and detection methods ; (2) Combine CEP290 antibody staining with tissue-specific markers to identify cell type-specific expression patterns; (3) Use laser capture microdissection followed by Western blotting to analyze CEP290 expression in specific cell populations; (4) Implement proximity ligation assays to identify tissue-specific interaction partners; (5) Conduct tissue-specific knockdown/knockout experiments followed by antibody-based validation and phenotypic analysis; and (6) Correlate CEP290 expression with tissue-specific functional readouts, as demonstrated by the link between olfactory CEP290 localization and smell function in LCA patients . This multi-faceted approach can explain why CEP290 mutations manifest differently across tissues, causing primarily retinal defects in some patients while affecting multiple organs in others .

How can advanced microscopy techniques enhance CEP290 antibody-based research?

Advanced microscopy approaches include: (1) Super-resolution microscopy (STED, STORM, SIM) to resolve CEP290's precise localization within centrosomal and ciliary subdomains—particularly valuable for mapping interactions at the transition zone; (2) Expansion microscopy to physically enlarge specimens, allowing conventional microscopes to achieve super-resolution imaging of CEP290 and interaction partners; (3) Live-cell imaging with split-fluorescent protein complementation to visualize dynamic CEP290 interactions; (4) FRAP (Fluorescence Recovery After Photobleaching) analysis to assess CEP290 mobility and exchange rates at centrosomes and cilia; (5) Correlative light and electron microscopy (CLEM) to place CEP290 immunofluorescence signals in ultrastructural context; and (6) Light-sheet microscopy for rapid 3D imaging of CEP290 distribution in whole tissues or organoids. These techniques can resolve contradictory findings regarding CEP290 localization by providing nanoscale spatial resolution and temporal dynamics not possible with conventional microscopy.